Novo Nordisk’s New Diabetes Combo Shows Potential To Best Lilly’s Mounjaro
Fierce Competition In Diabetes And Obesity Expected
New Phase II data shows combination of semaglutide plus a novel amylin analog outperforms semaglutide alone, and could surpass Lilly’s Mounjaro in helping weight loss in diabetes patients.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Axsome gets broad label for new depression drug; Argenx CEO on Vyvgart’s success; Chinese firms delist from US; solid results for Novo Nordisk’s new diabetes combo; and women leaders herald change at foreign firms in India.
Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.